Enter the advate.com Sweepstakes today for your chance to win one of five (5) grand prize vacation packages for four (4) to the 2006 National Hemophilia Foundation (NHF) Annual Meeting.
Each prize package includes airfare from an airport of Sponsor's choice to the NHF Annual Meeting to be held Oct. 12-14, 2006 in Philadelphia, Pennsylvania, three (3) nights hotel accommodations for four, and full registration into the annual meeting.
Make sure to register for the Sweepstakes monthly to increase your chances of winning! (One entry per person per month.)
Click here for Official Rules
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is the first and only plasma/albumin-free method recombinant factor VIII therapy indicated for the treatment of hemophilia A. ADVATE eliminates blood-borne pathogen risk that may be carried in blood-based additives by using a plasma/albumin-free method of processing.
ADVATE is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes. ADVATE is also indicated in the perioperative management of patients with hemophilia A. ADVATE is not indicated for the treatment of von Willebrand's disease.
Indications:
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes and for perioperative management of patients with hemophilia A.
ADVATE is not indicated for the treatment of von Willebrand’s disease.
Important Safety Information:
Let your doctor know if you have had any previous allergic reactions to other factor VIII products or mouse or hamster proteins.
The most common related adverse reactions observed during the ADVATE clinical studies include: strange taste in mouth, headache, dizziness, and redness in the face.
There is a possibility that you can have an allergic reaction to ADVATE. Symptoms of an allergic reaction may include rash, hives, itching, tightness in throat or chest, difficulty breathing, feeling dizzy or light-headed, or a weak pulse. If you experience any of these symptoms, stop the infusion immediately and promptly contact your doctor.
Contact your doctor if you are not able to prevent or control bleeding episodes with your regular doses of factor VIII therapy.
